216 related articles for article (PubMed ID: 34785638)
1. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus.
Zhu QY; Shan S; Yu J; Peng SY; Sun C; Zuo Y; Zhong LY; Yan SM; Zhang X; Yang Z; Peng YJ; Shi X; Cao SM; Wang X; Zeng MS; Zhang L
Nat Commun; 2021 Nov; 12(1):6624. PubMed ID: 34785638
[TBL] [Abstract][Full Text] [Related]
2. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
3. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
4. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
5. An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus.
Snijder J; Ortego MS; Weidle C; Stuart AB; Gray MD; McElrath MJ; Pancera M; Veesler D; McGuire AT
Immunity; 2018 Apr; 48(4):799-811.e9. PubMed ID: 29669253
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies.
Sathiyamoorthy K; Jiang J; Möhl BS; Chen J; Zhou ZH; Longnecker R; Jardetzky TS
Proc Natl Acad Sci U S A; 2017 Oct; 114(41):E8703-E8710. PubMed ID: 28939750
[TBL] [Abstract][Full Text] [Related]
7. A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge
Hong J; Zhong L; Zheng Q; Wu Q; Zha Z; Wei D; Chen H; Zhang W; Zhang S; Huang Y; Chen K; Chen J; Li S; Zeng MS; Zeng YX; Xia N; Zhang X; Xu M; Chen Y
J Virol; 2022 Apr; 96(8):e0007522. PubMed ID: 35348362
[TBL] [Abstract][Full Text] [Related]
8. Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection.
Zhao GX; Fang XY; Bu GL; Chen SJ; Sun C; Li T; Xie C; Wang Y; Li SX; Meng N; Feng GK; Zhong Q; Kong XW; Liu Z; Zeng MS
Cell Rep Med; 2024 May; 5(5):101573. PubMed ID: 38776874
[TBL] [Abstract][Full Text] [Related]
9. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus.
Edwards KR; Schmidt K; Homad LJ; Kher GM; Xu G; Rodrigues KA; Ben-Akiva E; Abbott J; Prlic M; Newell EW; De Rosa SC; Irvine DJ; Pancera M; McGuire AT
Cell Rep Med; 2024 Jun; 5(6):101587. PubMed ID: 38781964
[TBL] [Abstract][Full Text] [Related]
11. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes.
Mutsvunguma LZ; Rodriguez E; Escalante GM; Muniraju M; Williams JC; Warden C; Qin H; Wang J; Wu X; Barasa A; Mulama DH; Mwangi W; Ogembo JG
Virology; 2019 Oct; 536():1-15. PubMed ID: 31377598
[TBL] [Abstract][Full Text] [Related]
12. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
13. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition.
Chen WH; Kim J; Bu W; Board NL; Tsybovsky Y; Wang Y; Hostal A; Andrews SF; Gillespie RA; Choe M; Stephens T; Yang ES; Pegu A; Peterson CE; Fisher BE; Mascola JR; Pittaluga S; McDermott AB; Kanekiyo M; Joyce MG; Cohen JI
Immunity; 2022 Nov; 55(11):2135-2148.e6. PubMed ID: 36306784
[TBL] [Abstract][Full Text] [Related]
15. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
16. Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion.
Zhang X; Hong J; Zhong L; Wu Q; Zhang S; Zhu Q; Chen H; Wei D; Li R; Zhang W; Zhang X; Wang G; Zhou X; Chen J; Kang Y; Zha Z; Duan X; Huang Y; Sun C; Kong X; Zhou Y; Chen Y; Ye X; Feng Q; Li S; Xiang T; Gao S; Zeng MS; Zheng Q; Chen Y; Zeng YX; Xia N; Xu M
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2202371119. PubMed ID: 35917353
[TBL] [Abstract][Full Text] [Related]
17. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice.
Wei CJ; Bu W; Nguyen LA; Batchelor JD; Kim J; Pittaluga S; Fuller JR; Nguyen H; Chou TH; Cohen JI; Nabel GJ
Sci Transl Med; 2022 May; 14(643):eabf3685. PubMed ID: 35507671
[TBL] [Abstract][Full Text] [Related]
18. Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region.
Hong J; Wei D; Wu Q; Zhong L; Chen K; Huang Y; Zhang W; Chen J; Xia N; Zhang X; Chen Y
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960650
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies against EBV gp42 show potent
Wu Q; Zhong L; Wei D; Zhang W; Hong J; Kang Y; Chen K; Huang Y; Zheng Q; Xu M; Zeng MS; Zeng YX; Xia N; Zhao Q; Krummenacher C; Chen Y; Zhang X
Emerg Microbes Infect; 2023 Dec; 12(2):2245920. PubMed ID: 37542379
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells.
Bu W; Kumar A; Board NL; Kim J; Dowdell K; Zhang S; Lei Y; Hostal A; Krogmann T; Wang Y; Pittaluga S; Marcotrigiano J; Cohen JI
Immunity; 2024 Mar; 57(3):559-573.e6. PubMed ID: 38479361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]